Pol I / pre-rRNA synthesis longevity research
exploratoryresearch program · low · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether reducing the metabolic burden of rRNA synthesis can promote healthy longevity and metabolic health.
Restriction of RNA polymerase I-mediated pre-rRNA synthesis studied using multi-omics and functional tests in Caenorhabditis elegans and human primary cells.
Publication in Nature Communications reported that reduced pre-rRNA synthesis remodels the lipidome, preserves mitochondrial function, and extends lifespan in C. elegans, with improved energy homeostasis and metabolic plasticity in human primary cells.
Reduced pre-rRNA synthesis promoted longevity and metabolic health markers; enhancing pre-rRNA synthesis improved young nematode growth/performance but accelerated metabolic decline, mitochondrial stress, and premature aging.
Genome integrity preservation program
undisclosedplatform · high · Mon Oct 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Protect cells from genome damage and prevent or treat diseases of ageing by preserving genome integrity.
Approaches described include enhancing cellular DNA damage repair, protecting cells from damage, and addressing mutations, structural variations, epigenetic drift, and information loss.
LifeSpan Vision Ventures announced an investment in Matter Bio, describing the company as focused on preserving genome integrity.
Genome integrity therapeutics platform
preclinicalplatform · high · Mon Oct 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Preserve genomic integrity by protecting cells from DNA damage and addressing accumulated genome damage implicated in diseases of ageing.
Uses gene editing and sequencing technologies; focuses on mutations, structural variations, epigenetic drift, and other genomic information loss.
Seed funding/investment reported, with funds intended to support IND filing and initiation of a Phase 1/2a trial targeting solid cancers.
Accurate mutation sequencing program
exploratorybiomarker · medium
Measure or identify somatic mutations accurately as part of Matter Bio's longevity work around genome damage.
Accurate mutation sequencing; no assay format or platform implementation details are provided in the supplied material.
ShareLab described Matter Bio as working on accurate mutation sequencing.
Endogenous DNA repair improvement program
exploratoryresearch program · high
Improve endogenous DNA repair to reduce accumulated genome damage associated with ageing.
Enhancement of cellular/endogenous DNA damage repair; specific targets or modalities are not disclosed in the supplied material.
Matter Bio's site and ShareLab description identify improving DNA repair as a company work area.
Lm-TT Immunotherapy for pancreatic therapy
preclinicaldrug program · medium
Advance an immunotherapy for pancreatic therapy/cancer into clinical development.
Lm-TT immunotherapy; specific intervention details are not provided in the supplied material.
Matter Bio filed its first IND for Lm-TT Immunotherapy and described the pancreatic therapy as being taken to clinic.
Solid cancer genomic integrity therapeutic program
preclinicaldrug program · medium
Treat solid cancers as part of Matter Bio's approach to remove cells that are corrupted by genomic damage.
Therapeutic approach leveraging gene editing and sequencing technologies; specific agent or target not disclosed in the supplied material.
Planned IND application and Phase 1/2a clinical trial targeting solid cancers.
Somatic mutation and corrupted-cell removal program
exploratoryresearch program · high
Remove somatic mutations and remove cells that are corrupted or cancerous to address diseases of ageing and cancer.
Removal of corrupted cells, cancerous cells, and somatic mutations; specific therapeutic method is not disclosed in the supplied material.
Matter Bio's site states the goal of removing corrupted cells, and ShareLab describes work on removing somatic mutations and overly corrupted cells.